Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Cirrhosis

  Free Subscription

Articles published in Hepatology

Retrieve available abstracts of 253 articles:
HTML format

Single Articles

    September 2022
  1. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?"
    Hepatology. 2022 Sep 30. doi: 10.1002/hep.32813.

  2. VAZ K, Little R, Majeed A, Roberts S, et al
    Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis - does novelty supplant the standard?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32811.

    NGAL in AKI and cirrhosis - ready for prime time?
    Hepatology. 2022 Sep 28. doi: 10.1002/hep.32807.

  4. GAMBINO C, Piano S, Stenico M, Tonon M, et al
    Diagnostic and prognostic performance of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and AKI.
    Hepatology. 2022 Sep 20. doi: 10.1002/hep.32799.
    PubMed     Abstract available

  5. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    PubMed     Abstract available

  6. LIU Y, Zhang J, Xu Y, Lu X, et al
    Letter to the editor: Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients.
    Hepatology. 2022 Sep 14. doi: 10.1002/hep.32785.

  7. VIZZUTTI F, Celsa C, Battaglia S, Miraglia R, et al
    Reply to the Letter to the Editor: "Reflection on the unsatisfactory model predicting mortality after TIPS in cirrhotic patients".
    Hepatology. 2022 Sep 13. doi: 10.1002/hep.32784.

  8. DUAN Z
    Postvaccination COVID-19 related mortality in patients with cirrhosis:who is the culprit?
    Hepatology. 2022 Sep 5. doi: 10.1002/hep.32750.

    Will inhibition of cellular crosstalk resolve liver fibrosis?
    Hepatology. 2022;76:558-560.

  10. LIN Y, Dong MQ, Liu ZM, Xu M, et al
    A strategy of vascular-targeted therapy for liver fibrosis.
    Hepatology. 2022;76:660-675.
    PubMed     Abstract available

    August 2022
  11. JOHN BV, Dahman B
    COVID-19 related mortality in Cirrhosis is not associated with Proton Pump Inhibitor Exposure.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32748.

  12. LO GH
    Could COVID-19 vaccination reduce post-infection mortality in most cirrhotic patients ?
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32751.

  13. JOHN BV, Dahman B
    COVID-19 Vaccination and mortality in Decompensated Cirrhosis.
    Hepatology. 2022 Aug 24. doi: 10.1002/hep.32749.

  14. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    PubMed     Abstract available

  15. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    PubMed     Abstract available

  16. VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
    Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
    PubMed     Abstract available

  17. PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
    Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
    Hepatology. 2022;76:E51-E52.

  18. JINDAL A
    Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Hepatology. 2022;76:E42.

  19. GUIDOTTI LG, La Vecchia C, Colombo M
    Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
    Hepatology. 2022;76:300-302.

  20. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    PubMed     Abstract available

  21. VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
    Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
    Hepatology. 2022;76:418-428.
    PubMed     Abstract available

  22. PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
    Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
    Hepatology. 2022;76:456-468.
    PubMed     Abstract available

  23. GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
    Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
    Hepatology. 2022;76:372-386.
    PubMed     Abstract available

  24. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    PubMed     Abstract available

  25. ZHANG X, Wong GL, Yip TC, Tse YK, et al
    Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
    Hepatology. 2022;76:469-482.
    PubMed     Abstract available

    July 2022
  26. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    PubMed     Abstract available

  27. CHANG D, Truong E, Mena EA, Pacheco F, et al
    Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
    Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
    PubMed     Abstract available

  28. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    PubMed     Abstract available

  29. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.

    June 2022
  30. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    PubMed     Abstract available

  31. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
    Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
    Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
    PubMed     Abstract available

  32. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
    The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
    Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
    PubMed     Abstract available

  33. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
    Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
    Hepatology. 2022;75:1480-1490.
    PubMed     Abstract available

    May 2022
  34. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
    Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
    PubMed     Abstract available

  35. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.

  36. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.

  37. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.

    April 2022
  38. ZHOU Y, Chu W, Wu X, Zhou H, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.

  39. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.

  40. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Hepatology. 2022;75:1068-1069.

  41. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.

  42. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    PubMed     Abstract available

  43. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    PubMed     Abstract available

    March 2022
  44. CULLARO G, Hsu CY, Lai JC
    Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
    PubMed     Abstract available

  45. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
    Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
    PubMed     Abstract available

  46. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
    Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
    PubMed     Abstract available

  47. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
    Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
    PubMed     Abstract available

  48. HE Q, Zhang F, Shu J, Li S, et al
    Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
    PubMed     Abstract available

  49. LV Y, Chen H, Luo B, Bai W, et al
    Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
    PubMed     Abstract available

  50. BEKKI Y, Fenig Y
    Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
    Hepatology. 2022;75:754.

  51. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    PubMed     Abstract available

  52. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
    Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Hepatology. 2022;75:661-672.
    PubMed     Abstract available

    February 2022
  53. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.

  54. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    PubMed     Abstract available

  55. NOUREDDIN M, Abdelmalek MF
    ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.

  56. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
    Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
    PubMed     Abstract available

  57. ZANETTO A, Campello E, Spiezia L, Burra P, et al
    Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.

  58. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available

  59. LEMOINE CP, Superina R
    Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.

  60. ROGAL S, Hansen L, Patel A, Ufere NN, et al
    AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
    Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.

  61. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available

  62. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
    Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
    Hepatology. 2022;75:379-390.
    PubMed     Abstract available

  63. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
    Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    Hepatology. 2022;75:419-429.
    PubMed     Abstract available

    January 2022
  64. DE A, Keisham A, Duseja A
    Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.

  65. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available

  66. KUMAR A, Sharma P, Arora A
    Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.

  67. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available

  68. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
    Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
    PubMed     Abstract available

  69. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
    Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
    PubMed     Abstract available

  70. NG CH, Xiao J, Lim WH, Chin YH, et al
    Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
    PubMed     Abstract available

  71. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    PubMed     Abstract available

    December 2021
  72. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
    Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.

  73. KODAMA T, Takehara T
    Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.

  74. FRIEDMAN SL, Pinzani M
    Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
    PubMed     Abstract available

  75. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.

  76. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    PubMed     Abstract available

  77. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
    Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
    Hepatology. 2021;74:3301-3315.
    PubMed     Abstract available

    November 2021
  78. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    PubMed     Abstract available

  79. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    PubMed     Abstract available

  80. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    PubMed     Abstract available

  81. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed     Abstract available

  82. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
    Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
    Hepatology. 2021;74:2714-2724.
    PubMed     Abstract available

  83. KNIGHT GM, Clark J, Boike JR, Maddur H, et al
    TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.
    Hepatology. 2021;74:2735-2744.
    PubMed     Abstract available

  84. SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
    Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Hepatology. 2021;74:2410-2423.
    PubMed     Abstract available

  85. JAGDISH RK, Maras JS, Sarin SK
    Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
    Hepatology. 2021;74:2848-2862.
    PubMed     Abstract available

    October 2021
  86. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available

  87. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    PubMed     Abstract available

    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    PubMed     Abstract available

  89. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    PubMed     Abstract available

  90. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    PubMed     Abstract available

  91. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available

  92. EDELSON JC, Rockey DC
    Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
    Hepatology. 2021;74:2313-2314.

  93. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.

  94. WALTER A, Rudler M, Olivas P, Moga L, et al
    Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
    Hepatology. 2021;74:2085-2101.
    PubMed     Abstract available

  95. COLUCCI S, Altamura S, Marques O, Dropmann A, et al
    Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
    Hepatology. 2021;74:2186-2200.
    PubMed     Abstract available

  96. CHOI WM, Ryu T, Lee JH, Shim YR, et al
    Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
    Hepatology. 2021;74:2170-2185.
    PubMed     Abstract available

  97. DINANI AM, Kowdley KV, Noureddin M
    Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
    Hepatology. 2021;74:2233-2240.
    PubMed     Abstract available

  98. LUO X, Xiang T, Wu J, Wang X, et al
    Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2021;74:2074-2084.
    PubMed     Abstract available

    September 2021
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    PubMed     Abstract available

  100. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    PubMed     Abstract available

  101. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    PubMed     Abstract available

  102. ZHANG X, Yang H, Zeng S, Tian S, et al
    Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
    Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
    PubMed     Abstract available

  103. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    PubMed     Abstract available

  104. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    PubMed     Abstract available

  105. STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
    The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Hepatology. 2021;74:1533-1545.
    PubMed     Abstract available

  106. LIU Y, Song J, Yang J, Zheng J, et al
    Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
    Hepatology. 2021;74:1300-1318.
    PubMed     Abstract available

    August 2021
  107. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    PubMed     Abstract available

  108. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed     Abstract available

  109. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    PubMed     Abstract available

  110. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    PubMed     Abstract available

  111. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    PubMed     Abstract available

  112. CARTER J, Wang S, Friedman SL
    Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
    Hepatology. 2021;74:543-546.

  113. LIANG YJ, Teng W, Chen CL, Sun CP, et al
    Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Hepatology. 2021;74:641-655.
    PubMed     Abstract available

  114. TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
    Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
    Hepatology. 2021;74:1065-1073.

    July 2021
  115. WIN S, Min RWM, Zhang J, Kanel G, et al
    Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
    PubMed     Abstract available

  116. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available

  117. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available

  118. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available

  119. TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
    A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
    Hepatology. 2021;74:133-147.
    PubMed     Abstract available

  120. KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
    Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
    Hepatology. 2021;74:164-182.
    PubMed     Abstract available

  121. HOU X, Yin S, Ren R, Liu S, et al
    Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
    Hepatology. 2021;74:116-132.
    PubMed     Abstract available

  122. POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
    Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
    Hepatology. 2021;74:296-311.
    PubMed     Abstract available

    June 2021
  123. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available

  124. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    PubMed     Abstract available

  125. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available

  126. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available

  127. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available

  128. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available

  129. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    PubMed     Abstract available

  130. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available

  131. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    PubMed     Abstract available

  132. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    PubMed     Abstract available

  133. VUPPALANCHI R, Loomba R
    Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
    Hepatology. 2021;73:2095-2098.

  134. CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
    Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Hepatology. 2021;73:2196-2205.
    PubMed     Abstract available

  135. CHOI J, Yoo S, Lim YS
    Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Hepatology. 2021;73:2155-2166.
    PubMed     Abstract available

  136. CHO YE, Kim DK, Seo W, Gao B, et al
    Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
    Hepatology. 2021;73:2180-2195.
    PubMed     Abstract available

  137. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    PubMed     Abstract available

    May 2021
  138. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available

  139. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available

  140. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available

  141. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available

  142. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    PubMed     Abstract available

  143. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available

  144. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available

    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    PubMed     Abstract available

    April 2021
  146. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available

  147. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    PubMed     Abstract available

  148. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    PubMed     Abstract available

    March 2021
  149. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available

  150. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    PubMed     Abstract available

  151. ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
    Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
    PubMed     Abstract available

  152. WU H, Xu X, Zheng A, Wang W, et al
    TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
    PubMed     Abstract available

  153. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available

  154. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available

  155. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    PubMed     Abstract available

    February 2021
  156. NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
    Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
    PubMed     Abstract available

  157. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available

  158. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available

  159. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available

  160. LAN T, Yu Y, Zhang J, Li H, et al
    Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
    PubMed     Abstract available

  161. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available

  162. PARK H, Jiang X, Song HJ, Lo Re V 3rd, et al
    The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31732.
    PubMed     Abstract available

  163. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available

  164. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.

    January 2021
  165. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    PubMed     Abstract available

  166. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available

  167. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available

  168. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.

    December 2020
  169. ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
    Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
    Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
    PubMed     Abstract available

  170. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available

  171. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available

  172. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.

  173. VENTURA-COTS M, Abraldes JG, Bataller R
    Hepatology. 2020;72:2239-2240.

    November 2020
  174. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available

  175. HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
    DNA methylation profiling of human hepatocarcinogenesis.
    Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
    PubMed     Abstract available

  176. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available

  177. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available

  178. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available

  179. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available

  180. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available

  181. GAO J, Wei B, Liu M, Hirsova P, et al
    Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
    Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
    PubMed     Abstract available

  182. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    PubMed     Abstract available

  183. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    PubMed     Abstract available

    October 2020
  184. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    PubMed     Abstract available

  185. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available

  186. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available

  187. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Hepatology. 2020;72:1494-1495.

  188. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available

    September 2020
  189. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available

  190. LOK AS, Perrillo R, Lalama CM, Fried MW, et al
    medLow Incidence of Adverse Outcomes in Adults with Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31554.
    PubMed     Abstract available

  191. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    PubMed     Abstract available

  192. LAPOINTE-SHAW L, Chung H, Holder L, Kwong JC, et al
    Diagnosis of Chronic Hepatitis B Peri-Complication: Risk factors and Trends over Time.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31557.
    PubMed     Abstract available

  193. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    PubMed     Abstract available

  194. KUMAR M
    Hepatology. 2020;72:1160.

    August 2020
  195. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available

  196. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    PubMed     Abstract available

  197. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available

  198. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.

    July 2020
  199. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
    Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
    Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
    PubMed     Abstract available

  200. JIANG L, Lang S, Duan Y, Zhang X, et al
    Intestinal virome in patients with alcoholic hepatitis.
    Hepatology. 2020 Jul 12. doi: 10.1002/hep.31459.
    PubMed     Abstract available

  201. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available

  202. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.

  203. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Hepatology. 2020;72:364-365.

  204. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Hepatology. 2020;72:362-363.

  205. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.

    June 2020
  206. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available

  207. CHASCSA DM, Ferre EMN, Hadjiyannis Y, Alao H, et al
    APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data from a Large Predominantly American Cohort.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31421.
    PubMed     Abstract available

  208. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    PubMed     Abstract available

  209. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    PubMed     Abstract available

  210. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.

    May 2020
  211. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Hepatology. 2020;71:1884-1885.

    April 2020
  212. MELE D, Oliviero B, Mantovani S, Ludovisi S, et al
    Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.
    Hepatology. 2020 Apr 13. doi: 10.1002/hep.31273.
    PubMed     Abstract available

  213. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available

  214. SEHRAWAT TS, Arab JP, Liu M, Amrollahi P, et al
    Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31256.
    PubMed     Abstract available

  215. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.

  216. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.

    March 2020
  217. KAMAL H, Westman G, Falconer K, Duberg AS, et al
    Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214.
    PubMed     Abstract available

  218. TERKELSEN MK, Bendixen SM, Hansen D, Scott EAH, et al
    Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31215.
    PubMed     Abstract available

  219. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available

  220. WONG GL, Wong VW
    Hepatology. 2020;71:1134.

  221. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.

  222. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available

  223. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available

  224. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available

  225. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available

    February 2020
  226. SHARMA A, Verma AK, Kofron M, Kudira R, et al
    Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors.
    Hepatology. 2020 Feb 16. doi: 10.1002/hep.31188.
    PubMed     Abstract available

  227. DEBES JD, Boonstra A, de Knegt RJ
    NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.
    Hepatology. 2020 Feb 10. doi: 10.1002/hep.31170.
    PubMed     Abstract available

  228. KUMAR S, Verma AK, Rani R, Sharma A, et al
    Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis.
    Hepatology. 2020 Feb 7. doi: 10.1002/hep.31167.
    PubMed     Abstract available

  229. JOPHLIN LL, Cao S, Shah VH
    The transcriptome of hepatic fibrosis revealed by single cell RNA sequencing.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31155.
    PubMed     Abstract available

  230. STERLING RK, King WC, Wahed AS, Kleiner DE, et al
    Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.
    Hepatology. 2020;71:411-421.
    PubMed     Abstract available

  231. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available

    January 2020
  232. DOS SANTOS MARCON P, de Mattos AZ, Alves de Mattos A
    Letter to the editor: Co-infection of human immunodeficiency virus with hepatitis C virus: a change of paradigm.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31123.
    PubMed     Abstract available

  233. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Non-phagocytic Activation of NOX2 is Implicated in Progressive Non-alcoholic Steatohepatitis During Aging.
    Hepatology. 2020 Jan 17. doi: 10.1002/hep.31118.
    PubMed     Abstract available

  234. RATZIU V, Sanyal A, Harrison SA, Wong VW, et al
    Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.
    PubMed     Abstract available

    December 2019
  235. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available

  236. KARVAR S, Ansa-Addo EA, Suda J, Singh S, et al
    Moesin, an ERM family member, regulates hepatic fibrosis.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31078.
    PubMed     Abstract available

  237. PROESCHOLD-BELL RJ, Evon DM, Yao J, Niedzwiecki D, et al
    A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.
    Hepatology. 2019 Dec 5. doi: 10.1002/hep.31058.
    PubMed     Abstract available

    November 2019
  238. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available

    October 2019
  239. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available

  240. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available

    September 2019
  241. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available

  242. NAKANO Y, Kamiya A, Sumiyoshi H, Tsuruya K, et al
    A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30965.
    PubMed     Abstract available

  243. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available

  244. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available

  245. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available

  246. MOORING M, Fowl BH, Lum SZC, Liu Y, et al
    Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30928.
    PubMed     Abstract available

  247. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available

    August 2019
  248. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available

  249. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available

  250. MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
    Modelling progress towards elimination of hepatitis B in Australia.
    Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
    PubMed     Abstract available

    July 2019
  251. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available

    February 2019
  252. HARRISON SA, Rossi SJ, Paredes AH, Trotter JF, et al
    NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590.
    PubMed     Abstract available

    December 2018
  253. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Ghabril M, et al
    Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.